Invokana (Invokamet) is a drug used to treat Type 2 diabetes. It is an SGLT2 inhibitor used in combination with diet and exercise to improve glycemic control and lower blood sugar in adults with Type 2 diabetes mellitus. SGLT2 inhibitors lower a person’s blood sugar by causing the kidneys to remove it through the urine. The national Invokana (Invokamet) lawsuit alleges that the manufacturers and marketers of SGLT2 inhibitors failed to warn patients and physicians of the increased risks of kidney failure, myocardial infarction (heart attacks), other cardiovascular issues and ketoacidosis. The lawsuits states that if the manufacturers and marketers had properly warned of the risks, patients would have been prescribed and taken a substitute medication for their diabetes and would have had their health monitored on a more routine basis for potential signs of heart issues, renal impairment and high levels of ketones.